Basic and Clinical Neuroscience Journal
مجله علوم اعصاب پایه و بالینی
BCN
Medical Sciences
http://bcn.iums.ac.ir
137
journal137
2008-126X
2228-7442
10.32598/bcn
en
jalali
1388
10
1
gregorian
2010
1
1
1
2
online
1
fulltext
en
5HT3 antagonist for cognition improvement in schizophrenia: a double blind, placebo-controlled trial
5-HT3 antagonist for cognition improvement in schizophrenia: a double blind, placebo-controlled trial
Original
Original
<p style="text-align: justify; line-height: 15.6pt; background-image: initial; background-attachment: initial; background-size: initial; background-origin: initial; background-clip: initial; background-position: initial; background-repeat: initial;"><span style="font-size:12px;"><strong><span style="font-family: Tahoma, sans-serif;">Introduction:</span></strong><span class="apple-converted-space"><b><span style="font-family: Tahoma, sans-serif;"> </span></b></span><span style="font-family: Tahoma, sans-serif;">Patients with schizophrenia characteristically exhibit cognitive deficits. The level of cognitive impairment is found to predict the functional outcome of the illness more strongly than the severity of positive or negative symptoms. The purpose of this study was to assess the efficacy of ondansetron, a 5-HT3 receptor antagonist as an adjuvant agent in the treatment of chronic schizophrenia in particular for cognitive impairments.</span></span><span style="font-size: 10pt; font-family: Tahoma, sans-serif;"><strong><span style="font-family:"><!--stripped--><!--stripped--></span></strong></span></p>
<p style="text-align: justify; line-height: 15.6pt; background-image: initial; background-attachment: initial; background-size: initial; background-origin: initial; background-clip: initial; background-position: initial; background-repeat: initial;"><span style="font-size:12px;"><strong><span style="font-family: Tahoma, sans-serif;">Methods:</span></strong><span class="apple-converted-space"><b><span style="font-family: Tahoma, sans-serif;"> </span></b></span><span style="font-family: Tahoma, sans-serif;">This investigation was a 12-week, double blind study of parallel groups of patients with stable chronic schizophrenia. Thirty patients were recruited from inpatient and outpatient departments. All participants met Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia. To be eligible, patients were required to have been treated with a stable dose of risperidone as their primary antipsychotic treatment for a minimum period of 8 weeks. The subjects were randomized to receive ondansetron (8 mg/day) or the placebo in addition to risperidone. Cognition was measured by a cognitive battery. Patients were assessed at baseline and after 8, and 12 weeks after the medication started.</span></span><span style="font-size: 10pt; font-family: Tahoma, sans-serif;"><strong><span style="font-family:"><!--stripped--><!--stripped--></span></strong></span></p>
<p style="text-align: justify; line-height: 15.6pt; background-image: initial; background-attachment: initial; background-size: initial; background-origin: initial; background-clip: initial; background-position: initial; background-repeat: initial;"><span style="font-size:12px;"><strong><span style="font-family: Tahoma, sans-serif;">Results:</span></strong><span class="apple-converted-space"><b><span style="font-family: Tahoma, sans-serif;"> </span></b></span><span style="font-family: Tahoma, sans-serif;">Administration of ondansetron significantly improved visual memory based on improvement on visual reproduction, visual paired associate and figural memory sub tests of Wechsler Memory Scale Revised.</span></span><span style="font-size: 10pt; font-family: Tahoma, sans-serif;"><strong><span style="font-family:"><!--stripped--><!--stripped--></span></strong></span></p>
<p style="text-align: justify; line-height: 15.6pt; background-image: initial; background-attachment: initial; background-size: initial; background-origin: initial; background-clip: initial; background-position: initial; background-repeat: initial;"><span style="font-size:12px;"><strong><span style="font-family: Tahoma, sans-serif;">Discussion:</span></strong><span class="apple-converted-space"><b><span style="font-family: Tahoma, sans-serif;"> </span></b></span><span style="font-family: Tahoma, sans-serif;">The present study indicates ondansetron as potential adjunctive treatment strategy for chronic schizophrenia particularly for cognitive impairments.</span></span><span style="font-size: 10pt; font-family: Tahoma, sans-serif;"><!--stripped--><!--stripped--></span></p>
Cognitive impairments, 5- HT3, Schizophrenia
10
14
http://bcn.iums.ac.ir/browse.php?a_code=A-10-1-19&slc_lang=en&sid=1
Neyousha
Mohammadi
1370031947532846008172
1370031947532846008172
Yes
Maryam
Noroozian
1370031947532846008173
1370031947532846008173
No
Naregs
Karamghadiri
1370031947532846008174
1370031947532846008174
No
Shahin
Akhondzadeh
1370031947532846008175
1370031947532846008175
No